Guerbet commits to patients affected by infertility during the European Fertility Week

Guerbet (GBT), a global leader in medical imaging, commits to supporting patients affected by infertility during the 5th European Fertility Week taking place 2-8 November (#EuropeanFertilityWeek2020). Today, infertility [i] affects an estimated 186 million people worldwide. [ii] Many of them still have difficulties gaining access to information, diagnosis and appropriate treatment. [iii]
Guerbet underlines its commitment :

By supporting the work of patient organizations during fertility weeks:

o Fertility Europe and Fertility Network UK (United Kingdom) in Europe during #EuropeanFertilityWeek2020.
o Resolve (Etats-Unis) in the USA during #NIAW2020 (National Infertility Awareness Week).

These weeks are an opportunity to raise awareness of the problems faced by infertile people. They also draw attention to the need to improve access to information and education about fertility and infertility.

By setting up educational supports dedicated to patients such as:

o A webinar with the title «The patient journey in fertility management» which took place on October 20th (replay soon available here). The event brought together world-renowned medical experts and representatives of patient organisations to discuss the management of infertility.

o An innovative and educational website on hysterosalpingography (HSG), a key step within infertility management, prescribed at the beginning of the patient journey (hysterosalpingography.guerbet.com).

By supporting awareness-raising initiatives such as #THINKINGOFHAVINGABABY by the IFFS (International Federation of Fertility Societies). This initiative is the first global campaign for patients on fertility management during the Covid-19 pandemic. It encourages them to contact their health care team to seek advice and establish a plan for diagnostic tests and treatment in the pursuit of their care (read the interview with Dr Edgar Mocanu, President-Elect of the IFFS here).

In 2016 Guerbet launched its Women's Health Franchise with the ambition to improve the quality of infertility care and breast cancer surgery.
« We are proud to reinforce our commitment to those facing infertility. Our support to patient organizations and the creation of educational tools that provide easier access to information illustrate our commitment to being patient centric », emphasizes Jean-François Blanc, SVP of Interventional Imaging.

About Guerbet

Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €817 million in revenue in 2019. For more information about Guerbet, please visit http://www.guerbet.com.

Click here to subscribe